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Abstract
Background: GBV-C infection is associated with prolonged survival in HIV-infected people and GBV-C inhibits HIV
replication in co-infection models. Expression of the GBV-C nonstructural phosphoprotein 5A (NS5A) decreases surface
levels of the HIV co-receptor CXCR4, induces the release of SDF-1 and inhibits HIV replication in Jurkat CD4+ T cell lines.
Methodology/Principal Findings: Jurkat cell lines stably expressing NS5A protein and peptides were generated and HIV
replication in these cell lines assessed. HIV replication was significantly inhibited in all cell lines expressing NS5A amino acids
152–165. Substitution of an either alanine or glycine for the serine at position 158 (S158A or S158G) resulted in a significant
decrease in the HIV inhibitory effect. In contrast, substituting a phosphomimetic amino acid (glutamic acid; S158E) inhibited
HIV as well as the parent peptide. HIV inhibition was associated with lower levels of surface expression of the HIV co-
receptor CXCR4 and increased release of the CXCR4 ligand, SDF-1 compared to control cells. Incubation of CD4+ T cell lines
with synthetic peptides containing amino acids 152–167 or the S158E mutant peptide prior to HIV infection resulted in HIV
replication inhibition compared to control peptides.
Conclusions/Significance: Expression of GBV-C NS5A amino acids 152–165 are sufficient to inhibit HIV replication in vitro,
and the serine at position 158 appears important for this effect through either phosphorylation or structural changes in this
peptide. The addition of synthetic peptides containing 152–167 or the S158E substitution to Jurkat cells resulted in HIV
replication inhibition in vitro. These data suggest that GBV-C peptides or a peptide mimetic may offer a novel, cellular-based
approach to antiretroviral therapy.
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Introduction
Unlike most in vitro systems developed to study HIV replication,
humans infected with HIV are co-infected with a variety of
pathogenic and nonpathogenic microbes. These coinfections may
have unilateral or bidirectional interactions with HIV that may
alter the clinical outcome of either infection. For example, HIV
infection accelerates the course of hepatitis C virus (HCV) related
hepatic disease (reviewed in [1]), and is associated with an
increased prevalence of Kaposi’s sarcoma in people with
coexistent herpesvirus 8 (HHV-8) infection [2]. In contrast,
persistent infection with GB virus type C (GBV-C) is associated
with prolonged survival in HIV-infected individuals (reviewed in
[3] and [4]). Identification of the mechanism(s) by which microbial
coinfections inhibit HIV replication may identify novel therapeutic
targets or assist in the development of prevention strategies.
Microbial interactions may be direct, (e.g. the HIV tat protein
stimulates HHV-8 replication)[5] or indirect (cHV68 stimulates
prolonged production of the IFNc, upregulating the basal state of
innate immunity against subsequent infection)[6]. Several viral
infections inhibit HIV replication in vitro including HHV-6 [7],
HHV-7 [8], GBV-C [9–11], measles virus [12,13], and vaccina
virus [14]. Several of these infections alter HIV replication by
decreasing expression of HIV coreceptors and inducing chemo-
kines that compete with HIV for binding to entry receptors [10].
GBV-C is a common lymphotropic virus that may persist in
infected humans for decades, although the majority of immune
competent individuals clear viremia within two years of infection
(reviewed in [15]). Antibody to the envelope glycoprotein E2 is
usually detected following clearance of viremia, and detection of
this antibody is indicative of prior GBV-C infection (reviewed in
[1]). Viremia is present in approximately 2% of healthy blood
donors in the United States [16,17] and E2 antibodies are found in
another 9% to 12% of these donors [18–22]. GBV-C prevalence is
higher in developing countries and in U.S. populations that have
other blood-born or sexually transmitted infections [15]. For
example, approximately 20% of HCV-infected and up to 42% of
HIV-infected individuals are viremic in cross-sectional studies
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hepatitis, thorough investigation has failed to conclusively identify
an association between the virus and hepatitis, or any other human
disease [23].
On the basis of nucleotide sequence and predicted genome
organization, GBV-C is classified in the family Flaviviridae [16,17].
The virus replicates in human peripheral blood mononuclear cells
(PBMCs) including B and T lymphocytes (CD4+ and CD8+
subsets)[24–28] and co-infection of PBMCs with GBV-C and HIV
results in inhibition of HIV replication [9–11,29,30]. HIV inhibition
is mediated in part by downregulation of the HIV co-receptors
CCR5 and CXCR4 and by the induction of the ligands for these
chemokine receptors (RANTES, MIP-1a,M I P - 1 b,S D F -
1)[10,11,29,30]. Consequently, GBV-C co-infection of PBMCs
inhibits the replication of both CCR5- and CXCR4-tropic HIV
isolates (R5 and X4 respectively), and HIV isolates representing
clades A through H and the more divergent group O isolates [10,11].
GBV-C has a single strand, positive sense RNA genome
encoding a polyprotein of approximately 3000 amino acids [31].
GBV-C structural proteins reside at the amino terminal one third
of the polyprotein and are processed by cellular signal peptidases,
while the nonstructural proteins are processed by viral proteases
[32]. Two GBV-C proteins have been shown to inhibit HIV
replication in vitro [30,33]. Addition of the envelope glycoprotein
(E2) to CD4+ T cells inhibits R5 and X4 HIV isolates [30,34].
Infection with GBV-C and exposure of cells to E2 protein
decreased surface expression of the HIV entry coreceptor CCR5,
and also induced RANTES, one of the three known ligands for
CCR5. The mechanism by which E2 inhibits X4 viruses has not
been fully characterized [30]. In addition to E2, expression of the
GBV-C nonstructural phosphoprotein NS5A in a CD4+ T cell
line (Jurkat) potently inhibits HIV replication [33]. GBV-C NS5A
decreases surface expression of CXCR4, and increases the release
of SDF-1 (the CXCR4 ligand) into cell culture supernatants
[33,35]. In this study, we further characterize the GBV-C NS5A
peptide requirements involved in HIV inhibition by mutagenesis,
and determined that synthetic peptides are able to reproduce the
effects of the intracellularly expressed NS5A peptides.
Results
Characterization of the GBV-C NS5A domain required for
HIV inhibition
Previous studies demonstrated that stable expression of the
GBV-C NS5A protein in a CD4+ T lymphocyte cell line (Jurkat
cells) inhibited HIV replication [33]. The effect required protein
expression, as cells expressing GBV-C NS5A RNA in which a
frame-shift mutation that did not express NS5A did not inhibit
HIV [33]. Based on the expression of peptide deletions of NS5A,
the HIV inhibitory effect was mapped by sequential deletion
mutational analysis to amino acids 152–181 [33,35]. To further
characterize the region within this 30 amino acid NS5A sequence
responsible for HIV inhibition, Jurkat cell lines were generated
that stably expressed a number of NS5A peptides, including some
designed to mutate a specific amino acid. Representative NS5A
fragments previously described and seven new NS5A constructs
were used to generate stably expressing Jurkat cell lines in this
study as summarized in Fig. 1. The NS5A sequences were inserted
Figure 1. Summary of GBV-C NS5A proteins stably expressed in Jurkat – Tet-off cells. Boxes represent the amino acid region of GBV-C
NS5A expressed in cloned Jurkat cell lines. Full length NS5A is 414 amino acids in length (1–414). The 126 frame-shift-237 contains GBV-C NS5A
sequences that normally encodes these amino acids in the NS5A protein; however, a plus 1 frame shift was introduced so that the cells encode 26
missense amino acids. The amino acid sequence is shown for the 16mer peptide (152–167) and mutant peptides. Shaded boxes indicate cell lines in
which HIV replication was inhibited compared to vector controls. Boxes with cross-hatches represent cell lines that inhibited HIV replication
compared to controls, but significantly less than those cells indicated by solid shading. *=cell lines described previously.
doi:10.1371/journal.pone.0002580.g001
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promoter to drive transcription, and for which the GBV-C NS5A
sequences were expressed as the upstream open reading frame
(ORF) followed by stop codons, and an encephalomyocarditis
internal ribosomal entry site that directs translation of green
fluorescent protein (GFP) from the downstream ORF as previously
described [33]. HIV replication was significantly reduced in cell
lines expressing GBV-C NS5A amino acids 1–181, 152–181, 152–
167 and 152–165 when compared to HIV replication in three cell
lines containing the NS5A frame-shift RNA and cells expressing
NS5A amino acids 1–109 and 1–151 (Fig. 2). Thus all Jurkat cell
lines that expressed GBV-C NS5A peptides containing amino
acids 152–165 significantly inhibited HIV replication compared to
the vector and frame-shift controls. Cell lines that included GBV-
C NS5A coding regions that did not include NS5A amino acids
152–165 did not inhibit HIV (Fig. 2 and data not shown). Addition
of doxycycline to decrease GBV-C NS5A peptide expression
decreased the extent of HIV replication consistent with previous
experiments [33](data not shown). Thus expression of a 14 amino
acid region within the GBV-C NS5A protein (152–165) in this
CD4+ T cell line was sufficient to significantly inhibit HIV
replication. All HIV infections were performed in triplicate and
repeated at least twice with consistent results.
The GBV-C NS5A protein is predicted to be a phosphoprotein,
and expression of NS5A in cells results in two immunoreactive
proteins consistent with a basal and hyperphosphorylated state
[33,36]. The 152–167 NS5A peptide contains a serine residue at
position 158 that is predicted to be phosphorylated (http://www.
cbs.dtu.dk/services/NetPhos/). To assess whether this serine
residue is important for the HIV inhibitory effect, cell lines were
generated that expressed the NS5A 16mer 152–167
(VDGIPVSWDADARAPA) or mutated NS5A 16mer peptides
with nonconservative substitutions (S158A and S158G) or a
phosphomimetic substitution (S158E) [37]. A negative control cell
line was also generated that expressed the 152–167 amino acid
sequence in a scrambled order (DVIRAGPAWDSVAPAD) that is
not predicted to be phosphorylated (summarized in Fig. 1). Clonal
cell lines for each construct were selected that expressed the GFP
reporter gene (Fig. 3A). The relative expression of GFP varied
between cell lines, consistent with previous studies showing that
the larger the protein encoded in the upstream open reading frame
in a bicistronic vector, the lower the expression of the IRES-driven
downstream protein, in this case GFP [38]. Fig. 3B demonstrates
that the full-length NS5A, which had the lowest level of GFP
expression, expressed two immunoreactive proteins as shown
previously [36].
Because the anti-NS5A antibody used in Fig. 3B does not detect
the 16 amino acid NS5A peptides, additional testing was
Figure 2. HIV growth characteristics in selected Jurkat cell lines
expressing the GBV-C NS5A sequences. HIV replication in selected
cell lines expressing various GBV-C NS5A peptides summarized in Fig. 1
was assessed by monitoring HIV p24 antigen release into culture
supernatants. FS=the 126–237 frame-shift construct (see methods).
Numbers refer to the NS5A amino acid sequence expressed in each cell
line. *=HIV replication curves significantly less HIV p24 antigen than
the frame shift control. (P,0.01 for the three cell lines that included
amino acids 152–165 on days 3, 4, 5).
doi:10.1371/journal.pone.0002580.g002
Figure 3. Mutational analysis of GBV-C 152–167 NS5A peptide.
Clonal cell lines stably transfected with NS5A peptides were selected by
hygromycin resistance and examined for GFP expression (A). Cells
expressed the full length NS5A protein (amino acids 1–414), an NS5A 16
amino acid protein (152–167), the same 16 amino acids scrambled
(152–167scr), or peptides in which the serine (position 158) was
replaced with alanine (S158A), glycine (S158G) or glutamic acid (S158E).
VC=vector control cells and FS=frame-shift control cells. Background
represents the background fluorescence of parental Jurkat cells. Panel B
demonstrates two immunoreactive NS5A proteins in cells expressing 1–
414 (5A) but not in the vector control (VC) cells. Actin loading controls
are shown. HIV replication was significantly decreased in Jurkat cell lines
expressing full-length NS5A (1–414), the 152–167 peptide, and the
S158E mutant (*) compared to all other cell lines on days 5, 6, and 7
days post-infection (panel C). The S158A and S158G cell lines had
significantly less HIV replication than FS and VC ({; P=0.041 on day 7),
but significantly more HIV replication than the 1–414, 152–167, and
S158E cells ({;P ,0.02 for all, day 7).
doi:10.1371/journal.pone.0002580.g003
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First, cellular DNA from the Jurkat cell lines was amplified using
PCR primers upstream of the CMV promoter region and in the
downstream GFP coding region, and the product including the
entire GBV-C NS5A peptide coding region was sequenced as
previously described [33]. For all of the cell lines shown in
figure 3A, the NS5A peptide sequence was shown to be intact and
linked to both IRES and GFP sequences [33,35](data not shown).
Secondly, total cellular RNA from the cells containing the NS5A
peptides was extracted from each cell line, amplified by RT-PCR
and the amplified products sequenced. All of these cell lines
contained the NS5A mRNA linked to the CMV promoter and the
downstream GFP sequences. No sequences were amplified when
reverse transcriptase was not included in the buffer, thus
confirming that the GBV-C peptide RNA sequences were
transcribed in these cells (data not shown).
HIV replication was significantly inhibited in the cell lines
expressing the S158E peptide compared to vector control, frame-
shift control, S158A and S158G cell lines (Fig. 3C; p,0.01 for all;
T-test on days 5, 6, and 7). Jurkat cells expressing S158A and
S158G mutations also inhibited HIV replication compared to the
vector, frame-shift, and 152–167 scrambled peptide controls
(p=0.037 day 6 and p=0.043 day 7), but this inhibition was
significantly less than that observed in cells expressing the S158E
peptide (Fig. 3C; p=0.014 day 6, p=0.001 day 7). Thus although
the serine residue at position 158 appears to be important for
maximal HIV inhibition, mutation to nonconservative amino
acids did not completely abrogate the inhibitory effect.
To ensure that these results were not the result of cellular
abnormalities introduced during clonal selection, HIV replication
in the bulk cell lines that were used to generate the clonal cell lines
was analyzed. Figure 4A illustrates that HIV replication was
significantly inhibited in these cell lines, and confirmed that
expression of the GBV-C NS5A 152–167 peptide and the S158E
peptide inhibited HIV significantly more than the vector control,
scrambled peptide, and both S158G and S158A peptides
(p,0.001 days 3 through 6). However, the S158G and S158A
peptides were again shown to inhibit HIV replication when
compared to the vector and scrambled peptide control cell lines.
The pattern of HIV inhibition was not altered when HIV infection
was allowed to proceed longer in the clonal Jurkat cell lines (up to
20 days; Fig. 4B).
Consistent with prior studies [33], expression of full-length and
NS5A peptides did not have any morphologic effects on Jurkat
cells nor did they alter viability. Specifically, cell number increased
equally between vector control and NS5A-expressing cell lines
after five days in culture, and .98% of cells were viable by MTT
and trypan blue exclusion analyses for all cell lines (data not
shown).
To determine if GBV-C NS5A expression was specific for HIV
replication inhibition, Jurkat cells stably expressing the full-length
GBV-C NS5A (1–414), the 152–181 NS5A peptide, vector control
(expressing GFP), and parental Jurkat cells were infected with
mumps virus (MOI=1.0; Jeryl-Lynn [vaccine] strain). The
infectious titer of mumps in culture supernatants four days post-
infection in Vero cells demonstrated that mumps replicated
equally well in the parent, vector control, and the NS5A (152–
181) Jurkat cell lines (Fig. 5A). Interestingly, the mumps titer was
reproducibly higher in cells expressing full-length GBV-C NS5A
(1–414)(p=0.029), indicating that GBV-C NS5A somehow
enhanced mumps virus replication (Fig. 4A). Since GBV-C
NS5A 152–181 and 1–414 expression inhibited HIV replication,
the enhancement in mumps replication appears to be mediated by
a different region within NS5A. To further assess the specificity of
the HIV inhibition, VSV-G pseudotyped HIV particles containing
a luciferase reporter gene were prepared and assessed for their
ability to transduce the various cell lines. Non-enveloped HIV
particles containing the luciferase reporter served as the negative
control particles. Figure 5B demonstrates that VSV-G transduc-
tion efficiency was not statistically different in any of the NS5A
expressing cells compared to the vector control, irrespective of
their HIV inhibitory phenotype.
GBV-C NS5A peptide expression and chemokine
receptors
Expression of GBV-C NS5A in Jurkat cells was previously
shown to downregulate CXCR4 surface expression [33]. Jurkat
cell lines were examined by flow cytometry to determine if the
GBV-C NS5A peptides altered surface expression of HIV co-
receptors CXCR4 and CCR5. CXCR4 was reduced on cells
expressing the GBV-C NS5A peptides in which HIV replication
was most potently inhibited, but not in control cell lines or in cell
lines expressing the S158A, S158G, or scrambled peptides (Fig. 6).
CCR5 was not detected on any of the Jurkat cell lines including
the parent cell line (data not shown).
Figure 4. Expression of GBV-C NS5A peptides and HIV
replication. To ensure that HIV inhibition was not due to abnormal-
ities selected for during clonal selection of cell lines, HIV replication was
assessed in the bulk cell lines that expressed the GBV-C NS5A 152–167
peptide, the scrambled peptide (152–167Scr), and the mutated
peptides (S158A, S158G, S158E) and compared to the vector control
cell line (VC) (panel A). The pattern of HIV inhibition did not change
appreciably when infections were followed for up to 20 days (panel B).
1–414=cells expressing the full-length GBV-C NS5A and FS=cells
expressing the GBV-C NS5A frame shift control.
doi:10.1371/journal.pone.0002580.g004
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which CXCR4 expression was diminished, including cell lines that
express GBV-C NS5A amino acids 152–165, 152–167, and 152–
181 (fig. 7A) compared to the vector and frame-shift controls
(p,0.01 for all three). Consistent with these findings, cells
expressing the full-length NS5A (1–414), 152–167 and the
S158E phosphomimetic substitution induced SDF-1 release
compared to the cells expressing the vector control, the scrambled
peptide, S158A, and S158G peptides and the frame-shift
sequences (Fig. 7B; p,0.02 for all). There was variability in the
amount of SDF-1 released in different experiments; however, the
pattern of induction was similar between experiments. Cell lines
expressing the parental NS5A sequences including 152–165
released significantly more SDF-1 than the vector, frame-shift
and scrambled peptide controls when maintained in culture. The
S158A and S158G peptides did not induce SDF-1, even though
HIV replication was reduced compared to controls (Fig. 7A). This
provides additional evidence that SDF-1 induction is not the sole
mechanism by which NS5A inhibits HIV replication in these cells.
Previous studies demonstrated that addition of $350 pg/mL
SDF-1 inhibited HIV replication in CD4+ cell culture [10], thus
the amount of SDF-1 released into supernatants is sufficient to
inhibit HIV replication. Of note, SDF-1 release did not increase
until days 4 or 5, further indicating that this is not the sole
mechanism of HIV inhibition. RANTES, MIP-1a and MIP-1b
were not detected in any of the culture supernatants (data not
shown).
Synthetic GBV-C NS5A peptides inhibit HIV replication
Based on our initial data demonstrating that an 85 amino acid
fragment within NS5A inhibits HIV replication [33], overlapping
peptides representing GBV-C NS5A amino acids 152–191, 172 to
211, and 197 to 236 were synthesized and tested for their ability to
inhibit HIV when added to CD4+ T cell lines. To test the peptides
in a cell line that supports high level HIV replication, MT-2 cells
were incubated with the three peptides for 24 hrs prior to HIV
infection and peptides were maintained in the media following HIV
infection. The peptide representing GBV-C NS5A amino acids
152–191, but not the other two NS5A overlapping peptides
inhibited HIV replication compared to the no peptide control on
the fifth day post-infection in a dose-dependent manner (37% at
10 mg/mL; 58% at 25 mg/mL and 71% at 50 mg/mL; figure 8A).
Although the magnitude of HIV inhibition was less than that
observed when the peptides were expressed within Jurkat cells, the
inhibition was statistically significant (p,0.01 at 25 and 50 mg/ml).
To further assess if the timing that peptides were added to cells,
or if the type of CD4+ T cell line influenced the inhibitory effect,
Jurkat cells were incubated with the inhibitory peptide (152–191)
24 hrs prior to HIV infection or at the time of HIV infection.
Following HIV infection, cells were washed and incubated either
with or without the peptide. As expected the magnitude of HIV
replication was significantly lower in the control Jurkat cells
compared to the control MT-2 cells (Fig. 8B). However, a similar
pattern of HIV inhibition by the 152–191 NS5A peptide was
observed in cells incubated with the peptide for 24 hrs prior to
HIV infection compared to controls. This inhibition persisted for
the first 4 days post infection, whether or not the peptide was
Figure 5. The inhibitory effect of NS5A expression is specific
for HIV replication. The infectious titer of mumps virus was not
inhibited in Jurkat cells expressing full-length GBV-C NS5A (1–414) or
the 152–181 NS5A peptide compared to the vector control (VC) or
parent Jurkat cells (A). Mumps virus replication was increased in Jurkat
cells expressing full-length NS5A (*; p=0.029). Similarly, panel B
demonstrates that VSV-G pseudotyped retroviruses transduced all
NS5A and control cell lines with similar efficiency as measured by
relative luciferase activity in VSV-G pseudotype particles relative to the
no-envelope control particles (p.0.05 for all compared to VC). 152–
167=cells expressing this NS5A 16mer peptide, Scr=cells expressing
scrambled 16mer peptide, and S-A, S-G, S-E=cells expressing the
S158A, S158G, and S158E substitutions.
doi:10.1371/journal.pone.0002580.g005
Figure 6. GBV-C NS5A peptides downregulate CXCR4 expres-
sion. Cells expressing the full-length NS5A (1–414), the 152–167 and
S158E peptide had significantly less CXCR4 on their surface than did
cells containing the vector control (VC), frameshift (FS), scrambled 152–
167 peptide sequence (Scr), or the S158G, and S158A peptides. Data
represent the mean fluorescent intensity of CXCR4 on the surface of
these cells measured by flow cytometry.
doi:10.1371/journal.pone.0002580.g006
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was lost by day 5 in cells maintained in media without peptide. In
contrast, addition of peptides to cells at the time of HIV infection
did not lead to significant differences in HIV replication from
controls during the first 4 days post-infection. Nevertheless, cells
maintained in peptide post-HIV infection demonstrated signifi-
cantly less HIV release on day 5, presumably due to inhibition of
cell-to-cell HIV spread (Fig. 8B).
Based on the deletion mapping and mutagenesis data (Figures 1
and 3), the active NS5A peptide mutant (S158E) and a control
(152–167scr) peptide were synthesized and tested for HIV
inhibition when added to cells 24 hrs prior to HIV infection
(concentration up to 50 mg/mL). Neither of these peptides
significantly inhibited HIV replication (data not shown). To
determine if this reflected poor uptake and/or degradation of the
peptides, the S158E peptide and the scrambled 152–167 peptide
were synthesized with an N-terminal Tat-protein-transduction
domain to improve cellular uptake [39], and the peptides were
conjugated to FITC to allow monitoring of cellular binding and
uptake. Both the Tat-S158E and Tat-152–167-scrambled fusion
peptides were taken up by MT-2 cells in a dose-dependent manner
(Fig. 9A and B). Cells incubated in the S158E peptide inhibited
HIV replication compared to the no peptide control (Fig. 9C),
albeit to a lesser extent than expression of the peptide within Jurkat
cells (Fig. 3). In contrast, the Tat-152–167scr fusion peptide did
not inhibit HIV (Fig. 9C), even though it’s cellular uptake was
similar to the S158E peptide (Fig. 9A and B). No cellular toxicity
or effect on viability was observed in MT-2 cells or Jurkat cells
incubated in either of the peptides (50 ug/ml) as determined by
cell counts, trypan blue exclusion, and MTT assay [9,25,40] (data
not shown).
Discussion
The protein requirement within the GBV-C NS5A protein that
is responsible for inhibiting HIV infection in vitro was further
characterized in this study. Expression of ten different NS5A
polypeptides containing amino acids 152–165 inhibited HIV in
Jurkat cells (Fig. 1); however, scrambling the amino acid order of
the 152–167 peptide abolished the inhibitory effect. Furthermore,
Figure 7. GBV-C NS5A peptides increase the release of stromal
cell-derived factor 1 (SDF-1). SDF-1 release into culture superna-
tants was significantly greater in cell lines expressing GBV-C NS5A
peptides 152–165, 152–167 and 152–181 compared to the vector
control (VC) or frame shift (FS) cell lines after 7 days in culture (* p,0.01
for all; panel A). Jurkat cells expressing full-length NS5A (1–414), the
152–167 peptide and the S158E mutant peptide also induced
significantly more SDF-1 than did cells expressing VC, FS or the
S158A and S158G peptides (B; * p,0.02 for all on day 7).
doi:10.1371/journal.pone.0002580.g007
Figure 8. GBV-C NS5A synthetic peptides inhibit HIV replica-
tion. Addition of a synthetic peptide representing GBV-C NS5A amino
acids 152–191 (P1) to MT-2 cells 1 hour before HIV infection resulted in
a dose-dependent inhibition of HIV replication (concentration of
peptide=10, 25, or 50 mg/ml; panel A). By comparison, overlapping
peptides including GBV-C NS5A amino acids 172 to 211 (P2) or amino
acids 197 to 236 (P3) did not inhibit HIV replication at 50 mg/mL. All HIV
replication was compared to cells incubated with no peptide (NP).
Addition of peptide 1 (amino acids 152–191) to Jurkat cells 24 hrs prior
to HIV infection [(1) HIV] resulted in inhibition of HIV on day 4 ({
p,0.05; panel B). In cells in which peptide was not included after HIV
infection (2 P), HIV inhibition was lost on day 5. When HIV and the
peptides were added to cells simultaneously (HIV+P), inhibition was not
observed on day 4; however, when the peptide was included in the
media (+P), HIV replication was inhibited by day 5 (* p,0.05 compared
to the NP control).
doi:10.1371/journal.pone.0002580.g008
GBV-C NS5 Peptide Inhibits HIV
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inhibitory function (Fig. 3B), since a phosphomimetic substitution
(S158E) inhibited HIV as well as the expression of either the full
length NS5A protein or the parent peptide. Of note, the parent
peptide and S158E peptide inhibited HIV significantly more than
the S158A and S158G peptides; however, these peptides also
inhibited HIV replication compared to the scrambled peptide,
frame-shift and vector controls (Fig. 3C, 4A and 4B). These data
are consistent with the hypothesis that the serine at position 158 is
important for the HIV inhibitory effect of this peptide, and suggest
that either phosphorylation or a structural motif of the peptide is
required for HIV inhibition. The GBV-C NS5A inhibition effect
was specific for HIV, as both mumps virus replication and the
transduction efficiency of VSV-G pseudotyped HIV particles was
not diminished in the NS5A expressing cells in which HIV
replication was inhibited. Interestingly, full-length NS5A (1–414)
enhanced mumps replication in Jurkat cells compared to parental
and vector control cells. To our knowledge, viral enhancement has
not been previously described for flavivirus NS5 proteins.
However, expression of HCV NS5A in a HepG2 cell line was
shown to enhance hepatitis B protein expression and virus
replication, potentially as a result of NS5A partial inhibition of
interferon responsiveness [41]. Ongoing studies are examining
potential mechanisms of the mumps virus replication enhance-
ment by GBV-C NS5A. Nevertheless, since the GBV-C 152–181
protein did not enhance mumps virus replication, the HIV
inhibitory domain within GBV-C NS5A is distinct from the
mumps-enhancing domain. This enhancement in mumps replica-
tion further emphasizes the data showing that NS5A expression is
not toxic to the Jurkat cells.
Although GBV-C NS5A protein function is not completely
understood; in the closely related HCV, NS5A is required for viral
replication and is part of the viral replication complex [42–44].
NS5A expression is confined to actively infected cells, which
comprise fewer than 5% of PBMCs in vitro [25,26] and an
unknown percent in vivo. Thus it is unlikely that the effect of GBV-
C NS5A expression is directly responsible for all of the effect of
GBV-C on HIV replication and disease progression. However,
because GBV-C NS5A and the NS5A peptides downregulate the
HIV co-receptor CXCR4 and induce the release of SDF-1, NS5A
protein expression would appear to have a bystander effect on cells
not infected with GBV-C. Consistent with these findings, previous
studies demonstrated that GBV-C infection of healthy PBMCs in
vitro resulted in the induction of SDF-1 [10,29], and prior studies
with full-length NS5A expressing Jurkat cells found that
neutralizing SDF-1 activity with neutralizing antibodies dimin-
ished but did not abolish the HIV inhibitory effect [33]. Thus,
additional mechanisms of HIV inhibition appear to be elicited by
the GBV-C NS5A protein.
Addition of a synthetic peptide representing GBV-C NS5A
152–191 amino acids and the S158E mutant peptide to Jurkat and
MT-2 cells reproducibly inhibited HIV replication, although to a
less extent than that observed when the peptides were expressed
intracellularly in Jurkat cells (Fig. 2, 3, 7, and 8). The S158E
peptide was not active by itself; however, the addition of a tat-
protein transduction domain to the amino terminus resulted in
HIV inhibition for the S158E peptide but not the 152–167scr
peptide. These data suggest, but do not prove that intracellular
uptake of the native peptide and/or degradation may have
contributed to it’s lack of efficiency.
The secondary structure of the 152–167 peptide and S158E
mutant is predicted to contain a beta-strand (DNAMan software,
Lynnon Biosoft). In contrast, the S158A, S158G, and 152–167scr
peptides are not predicted to form a beta strands, suggesting that a
critical peptidic structure is responsible for the HIV inhibitory
interaction. The activity of the S158E peptide appeared to be
potentially greater than the parent peptide (Fig. 4B). Comparison
of the probability of the predicted structures indicates that the
probability of a beta-strand is greater in the S158E peptide than
the parent peptide, suggesting that this substitution may result in a
more stable structure than the parent sequence. Alignments of the
GBV-C NS5A 152–167 amino acid sequence with NS5 sequences
of isolates representing related flaviviruses (HCV, Dengue virus,
yellow fever virus, and West Nile Virus) did not identify .32%
homology. In addition, Blast search (http://www.ncbi.nlm.nih.
gov/blast/Blast.cgi) of all proteins (non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF excluding environmental
samples from WGS projects) did not identify proteins sharing
homology with the 152–167 peptide or the S158E peptide.
Figure 9. Dose dependent inhibition of HIV replication by the
S158E mutant. MT-2 cells were incubated with three concentrations
(10, 25, and 50 mg/ml) of synthetic peptides containing GBV-C S158E (A)
or 152–167scr (B) amino acid sequences in which an N-terminal Tat-
protein transduction domain was included, and the peptides were
conjugated to FITC. Cells were washed one hour later and FITC was
monitored by flow cytometry. Cells were infected with HIV 24 hrs after
incubation, and dose related inhibition of HIV replication was observed
for the S158E peptide, but not the 152–167scr peptide compared to the
no peptide control (NP). * HIV p24 antigen area under the curve was
less than controls (p,0.01).
doi:10.1371/journal.pone.0002580.g009
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infected people in most studies conducted prior to the availability
of combination antiretroviral therapy [4], although some argue
that GBV-C is a marker of low HIV RNA [45] or high CD4
counts [46,47]. Demonstration that NS5A peptide expression
inhibits HIV replication adds to previous in vitro studies that
support a causal relationship between GBV-C viremia and
survival in HIV-infected individuals [4]. Like HIV, GBV-C
replicates in CD4+ lymphocytes and in addition, GBV-C
replicates in CD8+ T cells and B cells [26]. Since the NS5A
152–167 peptide induces the release of SDF-1 and downregulates
CXCR4 surface expression (figure 5, 6 and reference [33]), it is
reasonable to speculate that the bystander effect of NS5A
expression and chemokine modulation would influence HIV
replication in lymphoid tissue. Further studies to characterize the
structural requirements of the GBV-C 152–167 NS5A peptide,
and to identify intracellular interacting proteins are underway.
These data suggest that the GBV-C NS5A peptide may be useful
from a therapeutic standpoint. Because the peptide functions by
altering CXCR4 and inducing SDF-1 instead of inhibiting HIV
replicative enzymes, it may provide a therapeutic approach that is
more difficult for HIV to overcome by the selection of virus
mutations.
Materials and Methods
GBV-C NS5A proteins and peptides
The full length GBV-C NS5A protein coding sequence
(numbering based on AF121950) was previously amplified from
the plasma of an individual with GBV-C viremia, ligated into the
pTRE2-Hyg plasmid (Clontech, Inc., Mountain View, CA)
modified to include a stop codon after NS5A, followed by the
encephalomyocarditis virus (EMC) IRES element directing the
translation of green fluorescent protein (GFP) as described [33].
GBV-C NS5A deletion mutants were generated by using
convenient restriction sites as previously described [33], and all
of the peptide constructs were generated by ligating synthetic
oligonucleotides containing flanking NheI and NotI restriction
sites into the modified pTRE2-Hgy plasmid [33]. All sequences
were confirmed by automated fluorescent dye terminator cycle
sequencing (University of Iowa DNA Core Facility; Applied
Biosystems automated DNA sequencer 373A, Foster City, CA).
Tet-Off Jurkat cells (Clontech, Inc.) were transfected (Amaxa
nucleofection, Amaxa Inc., Gaithersburg, MD) with plasmids
containing NS5A sequences or with control sequences including
the vector control expressing GFP, or with a vector that contains
NS5A sequences with a single base insertion to create a frameshift
mutation as previously described [33]. Following selection in
hygromycin and neomycin (200 mg/ml each), bulk cell lines were
examined for GFP expression. Cell lines stably expressing GFP
were examined for support of HIV replication and CXCR4
surface expression, and clonal cell lines were prepared by at least
two rounds of terminal dilution cloning.
To monitor NS5A expression, Jurkat cells were lysed in RIPA
buffer containing protease and phosphatase inhibitors, clarified
(13,0006g, 2 min at 4oC), and subjected to SDS-PAGE prior to
transfer to nitrocellulose membranes (Bio Rad, Inc., Hercules, CA)
as previously described [36]. Immunoreactive proteins were
identified using the GE3 anti-GBV-C NS5A rabbit serum kindly
provided by Dr. Jungsuh Kim (Genelabs Technologies, Inc.,
Redwood City, CA) which was generated against GBV-C
nucleotide sequences 6615–6977 expressed in E.coli. For cell lines
expressing NS5A fragments not detected by immunoblot,
expression of GFP was demonstrated by flow cytometry and total
cellular DNA and RNA was examined for linkage between NS5A
sequences and GFP using PCR or RT-PCR followed by
determination of the nucleotide sequence as previously described
[33,35]. DNA sequence alignments and predicted protein
secondary structure analyses employed DNAMan software
(Lynnen Biosoft, Inc., Pointe-Claire, Quebec, Canada).
Synthetic peptides representing NS5A amino acid sequences
were either kindly provided by Dr. Opendra Sharma and the NIH
Aids Reference Reagent Program or purchased (New England
Peptide LLC, Gardener MA or Iowa State University Protein
Facility, Ames, IA).
Virus infections
An HIV-1 isolate (X4, clade B; NIH AIDS Research and
Reference Reagent Program, catalog number 1073) was used to
infect CD4+ T cell lines (Jurkat cells and Jurkat cells expressing
GBV-C NS5A peptides or control plasmids, or MT-2 cells; 200 pg
HIV p24 antigen per 10
6 cells) as previously described [48].
Following HIV attachment, cells were washed, maintained in fresh
media and culture supernatants were obtained at various time
points to measure HIV-1 replication. HIV-1 replication was
determined by measuring HIV p24 antigen in culture supernatant
fluids (Retro-Tek HIV-1 p24 antigen ELISA kits, Zeptometrix,
Buffalo, NY) as previously described [9,10]. All infections were
performed in triplicate and were independently repeated at least
twice with consistent results.
Attenuated mumps virus (Jeryl-Lyn vaccine strain, Merck &
Co., Whitehouse Station, NJ) was purchased and a stock virus
preparation was generated to serve as a specificity control. The
infectious titer of this preparation was determined in Vero cells as
described by others [49]. The mumps virus preparation was used
to infect Jurkat cells including cell lines that expressed GBV-C
NS5A peptides or vector control cell lines.
Pseudotyped HIV particles were generated by transient
transfection of plasmid DNA into 293T cells plated 2 days prior
to transfection at a density of 1610
6 per 10-cm-diameter culture
dish. Two plasmid co-transfections were performed using 10 mgo f
HIV packaging construct (pNL4-3,Luc.R-E-; NIH AIDS Re-
search and Reference Reagent Program catalog # 3417) and
10 mg VSV-G envelope-expressing plasmid (pHEF-VSVG; NIH
AIDS Research and Reference Reagent Program catalog
#4693)[50]. HIV particles without an envelope served as the
control. DNA complexes were prepared with calcium chloride and
transfected into cells as described [50], and medium was replaced
4 h after transfection. Culture supernatants were harvested
72 hours after the start of transfection, filtered through a
0.45 mm Nalgene filter, and stored at 4uC prior to use. Jurkat
cells (8610
4 cells/well) were placed into a 24-well plate and
transduced with VSV-G pseudotyped HIV or the no-envelope
HIV (gag) particles. Cells were lysed with Glo-Lysis buffer
(Promega, Inc., Madison, WI) 72 hours after transduction and
relative luciferase activity assessed as recommended by the
manufacturer on a TD-20/20 Luminometer (Turner Biosystems,
Sunnyvale, CA).
Chemokines and chemokine receptors
CXCR4 and CCR5 expression on the surface of cells were
determined by flow cytometry as previously described [9].
Polyclonal rabbit anti-CCR5 (FITC-conjugated) and anti-CXCR4
(PE-conjugated) antibodies (BD Pharmingen, San Jose, CA) were
used in these studies. Flow cytometry was performed using a
FACScan (Becton Dickenson, San Jose, CA). SDF-1, RANTES,
MIP-1a and MIP-1b were detected in replicate culture superna-
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Statistics
Statistics were performed using SigmaStat software V3.11
(Jandel Scientific, Chicago, IL). HIV replication was analyzed by
measuring HIV p24 antigen release or infectious titer (mumps
virus) on various days post-infection, and comparisons were
performed using T-tests.
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